Breaks Categories: Stock Spotlights

FridayFeb 10, 2023 1:25 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Demonstrates Higher Absorption at Lower Dose Levels

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced it had demonstrated superior CBD blood absorption levels from its patented DehydraTECH(TM)-processed CBD compared to those of published comparators. “In their analysis, Lexaria’s researchers compared the average blood plasma levels of DehydraTECH-CBD at various dose levels (after the steady state or the amount of time needed before a consistent dose of drug achieves a stable plasma level had been reached) with that of non-Lexaria, pharmaceutical-grade CBD formulations published in two studies – a 2017 clinical trial and a 2019 study,” a recent article reads. “The 2017 trial evidenced an average blood plasma CBD…

Continue Reading

ThursdayFeb 02, 2023 1:31 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Elevate Drug Delivery Across Blood-Brain Barrier by ~1,900%

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed its patented DehydraTECH(TM) technology, which is designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. “DehydraTECH increases effectiveness and improves how these ingredients enter the bloodstream. Benefits of DehydraTECH include: improved speed of onset, with effects felt in minutes; increased bioavailability, with more of the drug delivered into the bloodstream; increased brain absorption, with testing suggesting up to 10x improvement; and improved drug potency, with more of the ingested product made available in the bloodstream requiring lower dosages,” a recent article reads. “Animal studies…

Continue Reading

TuesdayJan 24, 2023 11:13 am

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Working Toward Global Leadership in CBD Space

Flora (NASDAQ: FLGC) has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide, achieved under Luis Merchan’s tenure as CEO. “Merchan has also spearheaded several mergers and acquisitions, most notably JustCBD and Vessel Brand, which have since set the company up for rapid growth. Flora also secured $34.5 million in financing and signed deals with key retail distributors such as Tropi, a Colombia-based distributor, Walmart and Macy’s. The company also completed its first import of CBD-containing food and beverage products into the United States from Colombia under its Mambe brand. It has…

Continue Reading

ThursdayJan 12, 2023 2:32 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Closer Toward Broad Applications of Patented DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX) in 2022 achieved crucial milestones centered around its patented DehydraTECH(TM) drug delivery technology. “For Lexaria, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought Lexaria closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (‘IP’) portfolio received additional patent protection in different jurisdictions around the world. Lexaria also…

Continue Reading

MondayJan 09, 2023 1:13 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombia, US Facilities to Distinguish Itself Within Highly Competitive Space

Flora Growth Corp. (NASDAQ: FLGC), a cannabis cultivator and global distributor, is a rapidly growing house of brands building customer bases and distribution channels across international lines as it aims to distinguish itself within a highly competitive arena. “Much of Flora Growth’s strength lies in its licensed cultivation, extraction and isolation facility located in northern Colombia’s fertile climate, where an experienced labor force is helping the nation emerge from decades of drug war illicit trade into a recognized and regulated market,” a recent article reads. “From its 247 acres of growing fields, the company’s harvests move into a production pipeline…

Continue Reading

FridayDec 16, 2022 3:21 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Expected to Yield Notable Results in Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs. “Lexaria [recently] announced that the study program DIAB-A22-1 [had begun] on schedule, making it the company’s first-ever study to investigate whether its DehydraTECH-processed cannabidiol (‘CBD’) may potentially have therapeutic utility against diabetes,” a recent article reads. “Lexaria is optimistic that its DehydraTECH-CBD will yield notable results from this study, especially having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study. There is a strong connection between heart disease, hypertension and diabetes, with hypertension proving to…

Continue Reading

ThursdayDec 08, 2022 1:49 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Latest DehydraTECH-CBD Study May Be 1st to Evidence Sustained Drop in Blood Pressure

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs, has, since inception, been committed to addressing severe unmet patient needs. Hypertension has been one of its main focus areas. “Lexaria continues to move forward, most recently with the success in its latest human clinical study, HYPER-H21-4. The study may be the first to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (‘CBD’) therapy using the company’s patented DehydraTECH(TM) technology,” reads a recent article. “Since Lexaria began developing DehydraTECH…

Continue Reading

FridayNov 18, 2022 12:34 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Treatment Poised to Provide Reprieve to Millions of Patients

Lexaria Bioscience Corp. (NASDAQ: LEXX) is developing a potential hypertension treatment with little to no side effects. “The treatment is created by processing cannabidiol (‘CBD’) using the company’s patented DehydraTECH(TM) drug delivery technology, which has been shown to substantially increase the bioavailability of active pharmaceutical ingredients (‘APIs’). In human studies, Lexaria has shown that DehydraTECH-CBD not only increases the amount of CBD in the blood by as much as 317% but also reduces blood pressure and arterial stiffness,” a recent article reads. “Lexaria hopes to prove, through registered clinical trials, that its DehydraTECH-CBD formulation has an acceptable safety and tolerability…

Continue Reading

FridayNov 04, 2022 2:10 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Increasing Access to Safe, Legal CBD and THC to Global Consumers

Flora Growth Corp. (NASDAQ: FLGC) is a cannabis cultivator, brand manufacturer and global distributor. “The Canadian company with a productive base of operations in Colombia’s fertile greenbelt is licensed to cultivate cannabis on a 100-hectare (about 247-acre) farming facility and then deliver its product to its GMP-certified processing facility in the nation’s capital, where beauty, phytotherapeutic and nutraceutical products are prepared for market…. Flora’s brand division is focused on developing plant-based consumer products, such as cannabinoid-infused juices, gummies, topicals, inhalables, and skin care. But the company also prioritizes the manufacture of ‘cannabinoid-derived medical formulations that can be sold domestically and…

Continue Reading

FridayOct 21, 2022 3:20 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential to Represent Multiple Commercial Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a drug delivery platform innovator, last year announced a review of its successful 2021 antiviral drug program. “Lexaria specifically probed the bioavailability of five DehydraTECH(TM)-processed antiviral drugs for SARS-CoV-2, HIV/AIDS and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the bloodstream. The demonstrated improvements in absorption, Lexaria believed, could have significant commercial potential considering that many antiviral drugs typically show low oral bioavailability in their available form because of significant liver biotransformation and/or poor intestinal uptake,” reads a recent article. “Lexaria’s vision…

Continue Reading